SCHEMBL4969863

SCHEMBL4969863

O=C(NCCCc1ccccc1)C1(c2ccc(Cl)cc2)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.56
PLAAT3 P53816 1/20 0.54
PLAAT5 Q96KN8 1/20 0.54
PLAAT2 Q9NWW9 1/20 0.54
PLAAT4 Q9UL19 1/20 0.54
CNR2 P34972 1/20 0.54
SMN1; SMN2 Q16637 3/20 0.52
ALDH1A1 P00352 2/20 0.52
HTT P42858 3/20 0.51
KDM4E B2RXH2 1/20 0.51
GAA P10253 1/20 0.51
EPHX2 P34913 2/20 0.50
MEN1 O00255 1/20 0.50
LMNA P02545 1/20 0.50
MAPT P10636 1/20 0.50
KMT2A Q03164 1/20 0.50
MMP8 P22894 1/20 0.50
TRPA1 O75762 3/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
AVPR1A P37288 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4965067 0.92 PLAAT3 (0.57) CNR1PLAAT3PLAAT5PLAAT2PLAAT4
SCHEMBL14491537 0.90 PLAAT3 (0.56) CNR1PLAAT3PLAAT5PLAAT2PLAAT4
SCHEMBL14491525 0.84 SMN1; SMN2 (0.68) SMN1; SMN2HTTGAAEPHX2LMNA
SCHEMBL5350234 0.82 SMN1; SMN2 (0.64) CNR1PLAAT3PLAAT5PLAAT2PLAAT4
SCHEMBL378422 0.82 TACR1 (0.56) SMN1; SMN2HTTKDM4EGAAEPHX2
SCHEMBL4961884 0.81 SMN1; SMN2 (0.59) CNR1SMN1; SMN2ALDH1A1HTTKDM4E
SCHEMBL14491561 0.81 SMN1; SMN2 (0.56) PLAAT3PLAAT5PLAAT2PLAAT4SMN1; SMN2
SCHEMBL2469559 0.80 MEN1 (0.55) SMN1; SMN2ALDH1A1HTTEPHX2MEN1
SCHEMBL13067102 0.80 SMN1; SMN2 (0.66) SMN1; SMN2HTTLMNAMMP8L3MBTL1
SCHEMBL5351676 0.80 HDAC4 (0.61) CNR1SMN1; SMN2ALDH1A1HTTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050288338-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2005-12-29 US claimed
EP-1773780-A4 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2008-01-09 EP disclosed
EP-1773780-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-04-18 EP disclosed
WO-2006012227-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-02-02 WO disclosed
US-20050288338-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288338-A1 Amido compounds and their use as pharmaceuticals HSD11B1, CYP11B1, HSD11B2 CNR1 430/4885PLAAT3 668/4885PLAAT5 626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.